ClinicalTrials.gg
CompletedNCT05400226Updated Oct 17, 2024Results posted

Phase 2 Study of VGT-309 in Lung Cancer

A Phase 2 interventional study of VGT-309 in Lung Cancer, sponsored by Vergent Bioscience, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Vergent Bioscience, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,462 studies in Lung Neoplasms with a site in United States — 423 open to participants now, 644 under way, 52 of them phase 3. Lung Neoplasms · United States.

Enrollment
1,027th of 1,908
40 · median 48
Started
2022
with 118 others
Phase 2
633 of 2,462
71 open now
Registered
1,981st of 2,462
by date

Among the 2,462 studies in Lung Neoplasms with a site in United States, this one is the 1,027th largest by enrollment of the 1,908 interventional ones that give a count, is one of 119 that started in 2022, is one of 633 in phase 2, and was the 1,981st registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

423 of the 2,462 studies in Lung Neoplasms with a site in United States are open now. Recruiting first, the newest first:

418 more — sign in →

All 423 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,462 studies in Lung Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.

Read the detailed description

A Phase 2, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer in subjects undergoing lung cancer surgery. A total of 40 subjects will be enrolled to ensure at least 38 evaluable subjects with the option to expand enrollment by protocol amendment if deemed necessary to meet primary and/or secondary objectives.

Following agreement with and signing of the informed consent, subjects will undergo screening measurements for the study. Assessments include the following, unless they have been done within 4 weeks prior to the anticipated dosing:

  1. Medical, surgical and medication history.
  2. Complete physical exam, including vital signs and weight.
  3. Standard pre-operative chemistry, hematology, coagulation and urinalysis clinical laboratory studies.
  4. 12-lead ECG.
  5. Serum pregnancy test for females of child-bearing potential.

Following clearance of all enrollment criteria, each subject will receive an IV administration of 0.32 mg/kg VGT-309 at 12-36 hours prior to surgery (refer to section VGT-309 Dosing, below). Upon dosing, subjects will be observed for up to 2 hours and asked about possible treatment emergent adverse events.

Subjects will undergo surgical resection as planned and within the time specified following VGT-309 dosing. Measurements of efficacy will be taken during surgery and during the pathological examination of all surgical specimens.

Following surgery, subjects will be monitored for safety during their hospitalization. After discharge from the hospital, and approximately 14 days post-surgery, the subjects will be contacted by telephone to assess their well-being. Between 19 to 39 days post-surgery, subjects will either return to the clinic or participate in a telehealth visit for final safety assessments. If there are no adverse events requiring further follow up, subjects will then be released from the study.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to sign the and comply with study procedures.
  2. Be between the ages of 18 and 85, inclusive.
  3. Be male or female and meet the following conditions:

    1. Female participants must be of non-, or,
    2. If of childbearing potential be non-pregnant or non-lactating and agree to use highly effective from screening through Day 30.
    3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.
    4. Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:

      • Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
      • Intrauterine device or intrauterine hormone-releasing system
      • NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above.

    They are required to maintain abstinence from screening through Day 30.

  4. Have a lung nodule or mass that might be considered primary lung cancer or lung , whether or not it is -proven.
  5. Be scheduled to undergo standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent and meet all pre-operative surgical and anesthesia acceptance criteria.
  6. Have acceptable kidney and liver functions at study entry as evidenced by:

    1. /Aspartate Aminotransferase (ALT/AST) \< 1.5 times the
    2. Serum creatinine \< 1.5 times the upper limit of normal
  7. Have an (ECOG) score of 0-2.
  8. Meet all standard surgical and general anesthesia requirements.
  9. Have not participated in a clinical trial within the last 30 days.

Exclusion criteria

Exclusion Criteria:

  1. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
  2. They have a known allergy or reaction to indocyanine green (ICG), other radiographic contrast agent, or any component of VGT-309.
  3. Have congenital long syndrome or QTcF > 450ms (males) or >470ms (females) by history or at Screening .
  4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.
  5. Have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    0.32mg/kg VGT-309

    Single arm in an open label study

    Drug: VGT-309

Interventions

06

What researchers measure

Primary outcomes

  1. Clinically Significant Event (CSE)

    Identification of the proportion of subjects with at least one CSE as defined by: A. Localization of a Pulmonary Nodule using VGT-309 near-infrared (NIR) Imaging when white light and palpation failed to identify a nodule. B. Synchronous Lesion Identification using VGT-309 NIR Imaging when not identified by white light and palpation. C. Positive Margin Identification with only VGT-309 NIR Imaging when deemed negative by the surgeon by white light and palpation.

    Time frame: Day of surgery

Secondary outcomes

  1. Sensitivity

    Sensitivity is defined as the probability that tissue fluoresces intraoperatively when it is cancer as confirmed by histology. Sensitivity = (True Positive)/(True Positive + False Negative)

    Time frame: Day of surgery

  2. Negative Predictive Value

    Negative predictive value is defined as the probability that a tissue sample does not contain cancer on histologic exam if it does not fluoresce intraoperatively. Negative Predictive Value = (True Negative)/(True Negative + False Negative)

    Time frame: Day of surgery

  3. Specificity

    Specificity is defined as the probability that tissue does not fluoresce intraoperatively when it is not cancerous as confirmed by histology. Specificity = (True Negative)/(True Negative + False Positive)

    Time frame: Day of surgery

  4. Positive Predictive Value

    Positive predictive value is defined as the probability that a tissue sample contains cancer on histologic exam if it fluoresces intraoperatively. Positive Predictive Value = (True Positive)/(True Positive + False Positive)

    Time frame: Day of surgery

07

Results

Posted Oct 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneVGT-309
Started40
Dosing40
Surgery40
Completed40
Not completed0

Outcome measures

PrimaryClinically Significant Event (CSE)

Identification of the proportion of subjects with at least one CSE as defined by: A. Localization of a Pulmonary Nodule using VGT-309 near-infrared (NIR) Imaging when white light and palpation failed to identify a nodule. B. Synchronous Lesion Identification using VGT-309 NIR Imaging when not identified by white light and palpation. C. Positive Margin Identification with only VGT-309 NIR Imaging when deemed negative by the surgeon by white light and palpation.

Time frame:
Day of surgery
Reported as:
Number · Proportion of subjects
Clinically Significant Event (CSE)
Proportion of subjectsVGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery
Clinically Significant Event (CSE)0.425 (0.270 to 0.591)
Statistical analysis
  • VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery · Exact Binomial Test · p = < .0001 · Proportion: 0.425 · 95% CI 0.270 to 0.591The Parameter Dispersion Value is the asymptotic standard error of the proportion.
SecondarySensitivity

Sensitivity is defined as the probability that tissue fluoresces intraoperatively when it is cancer as confirmed by histology. Sensitivity = (True Positive)/(True Positive + False Negative)

Time frame:
Day of surgery
Reported as:
Number · Proportion of lesions
Sensitivity
Proportion of lesionsVGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery
Sensitivity0.850 (0.675 to 0.939)
Statistical analysis
  • VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery · Proportion: 0.850 · 95% CI 0.675 to 0.939
SecondaryNegative Predictive Value

Negative predictive value is defined as the probability that a tissue sample does not contain cancer on histologic exam if it does not fluoresce intraoperatively. Negative Predictive Value = (True Negative)/(True Negative + False Negative)

Time frame:
Day of surgery
Reported as:
Number · Proportion of lesions
Negative Predictive Value
Proportion of lesionsVGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery
Negative Predictive Value0.455 (0.202 to 0.733)
Statistical analysis
  • VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery · Proportion: 0.455 · 95% CI 0.202 to 0.733
SecondarySpecificity

Specificity is defined as the probability that tissue does not fluoresce intraoperatively when it is not cancerous as confirmed by histology. Specificity = (True Negative)/(True Negative + False Positive)

Time frame:
Day of surgery
Reported as:
Number · Proportion of lesions
Specificity
Proportion of lesionsVGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery
Specificity0.333 (0.126 to 0.633)
Statistical analysis
  • VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery · Proportion: 0.333 · 95% CI 0.126 to 0.633
SecondaryPositive Predictive Value

Positive predictive value is defined as the probability that a tissue sample contains cancer on histologic exam if it fluoresces intraoperatively. Positive Predictive Value = (True Positive)/(True Positive + False Positive)

Time frame:
Day of surgery
Reported as:
Number · Proportion of lesions
Positive Predictive Value
Proportion of lesionsVGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery
Positive Predictive Value0.773 (0.650 to 0.862)
Statistical analysis
  • VGT-309 0.32mg/kg IV Given 12-36 Hours Prior to Surgery · Proportion: 0.773 · 95% CI 0.650 to 0.862

Adverse events

Collected over Adverse events were collected from the time of dosing through completion of the End-of-Study Visit (Days 22-36). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VGT-309 0.32mg/kg0/40 (0%)8/40 (20%)40/40 (100%)
Most frequent serious events
Most frequent serious events
EventVGT-309 0.32mg/kg
PneumothoraxRespiratory, thoracic and mediastinal disorders3/40
IleusGastrointestinal disorders1/40
VomitingGastrointestinal disorders1/40
HypervolaemiaMetabolism and nutrition disorders1/40
Respiratory failureRespiratory, thoracic and mediastinal disorders1/40
HypoxiaRespiratory, thoracic and mediastinal disorders1/40
Traumatic haemothoraxInjury, poisoning and procedural complications1/40
Most frequent other events
Showing 10 of 31
Most frequent other events
EventVGT-309 0.32mg/kg
Procedural painInjury, poisoning and procedural complications40/40
PneumothoraxRespiratory, thoracic and mediastinal disorders25/40
HypotensionVascular disorders17/40
NauseaGastrointestinal disorders9/40
Urinary retentionRenal and urinary disorders7/40
DyspnoeaRespiratory, thoracic and mediastinal disorders6/40
HypoxiaRespiratory, thoracic and mediastinal disorders6/40
Sinus bradycardiaCardiac disorders6/40
VomitingGastrointestinal disorders5/40
HypomagnesaemiaMetabolism and nutrition disorders5/40

Baseline characteristics

One-time dose by IV infusion over 15-20 minutes using a syringe pump between 12-36 hours prior to the start of surgery

Age, Categorical
Age, Categorical(Participants)VGT-309 0.32mg/kg
<=18 years0
Between 18 and 65 years13
>=65 years27
Age, Customized
Age, Customized(years)VGT-309 0.32mg/kg
Age66 ± 10.51
Sex: Female, Male
Sex: Female, Male(Participants)VGT-309 0.32mg/kg
Female28
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VGT-309 0.32mg/kg
Hispanic or Latino1
Not Hispanic or Latino39
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VGT-309 0.32mg/kg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White29
More than one race0
Unknown or Not Reported4
Region of Enrollment
Region of Enrollment(participants)VGT-309 0.32mg/kg
United States40
Height
Height(cm)VGT-309 0.32mg/kg
Mean165.33 ± 13.863
Weight
Weight(kg)VGT-309 0.32mg/kg
Mean77.61 ± 23.658

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2023, 13 months.

Results were first posted in Oct 2024, 1 year 3 months after primary completion.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 13 months is below that.

Counting every sponsor, half of 362 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 1, 2022
StartActual
May 24, 2022
Primary completionActual
Jun 24, 2023
CompletionActual
Dec 15, 2023
Results first posted
Oct 17, 2024
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05400226
Lead sponsor
Vergent Bioscience, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
May 24, 2022
Primary completion
Jun 24, 2023
Completion
Dec 15, 2023
Results posted
Oct 17, 2024
Last update
Oct 17, 2024

Study contacts

Curt Scribner, MD
study director · Vergent Bioscience

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cathepsin-targeted Fluorescent Imaging Probe VGT-309

Start the discussion